search
Back to results

Efficacy of PENS of the Auricle as an Opioid Sparing Postoperative Analgesic Technique in Cancer Endometrium and Cancer Cervix Patients

Primary Purpose

Cancer of Endometrium, Cancer of Cervix

Status
Recruiting
Phase
Not Applicable
Locations
India
Study Type
Interventional
Intervention
Primary Relief
Primary Relief - Sham Device
Sponsored by
DyAnsys, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cancer of Endometrium

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria: Age >18 yrs Diagnosed with CA-endometrium OR CA -cervix of stage I/II and post RT CA cervix patients coming for hysterectomy Elective surgery Informed consent obtained ASA (American Society of Anaesthesiology) physical status 1-3 Exclusion Criteria: Patient refusal Cancer cervix other than the stages mentioned in inclusion criteria ASA PS >3 Emergency surgery, Laparoscopic and robotic procedures Unplanned postoperative ventilation Allergy/sensitivity to adhesive Active skin infection/lesion in the ear region H/O of seizure or cerebral disease H/O chronic pain and prolonged analgesic usage H/O opioid dependence H/O anxiety or psychiatric illness requiring treatment Pre-existing implantable/ electronic on demand device Patients who might require MRI in the study period Patients with transmissible diseases Patients with coagulopathies Absolute or relative contraindication to drugs used in the study

Sites / Locations

  • Cancer Institute,(Wia)Recruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Sham Comparator

Arm Label

Treatment Group

Control Group

Arm Description

The group who have received PENS treatment using PrimaryRelief in addition to Injection paracetamol in a dosage of 15mg/kg every 6th hourly. Break through pain with NRS>4 will be managed with injection tramadol at 1mg/kg followed by 0.5mg/kg after 10mins in cases of persisting pain.

The group who have received a sham device along with Injection paracetamol in a dosage of 15mg/kg every 6th hourly. Break through pain with NRS>4 will be managed with injection tramadol at 1mg/kg followed by 0.5mg/kg after 10mins in cases of persisting pain.

Outcomes

Primary Outcome Measures

Numeric Rating Scale (NRS)
The primary goal is to evaluate the efficacy of PENS treatment in the change in postoperative pain after cancer surgery compared to the control group. The pain is measured using the numerical rating scale (NRS). Pain Score will be measured on a scale (0 = no pain;10 = worst imaginable pain; lower scores indicate better outcome)

Secondary Outcome Measures

Overall Postoperative analgesia and opioid requirement
To evaluate the effect of treatment in reducing the overall postoperative analgesia and opioid requirement. We will record the total dose and duration of additional analgesics required from the immediate postoperative period till pod 4 in iv morphine equivalents.
Patient Ambulation
Evaluate the ease of patient ambulation by assessing associated Numeric Rating Scale (NRS) score (0 = no pain;10 = worst imaginable pain; lower scores indicate better outcome)
Record of Participant Bowel Movement Patterns
Onset of Bowel Movements - POD 1/POD 2/ POD 3/ > POD3
Richmond Agitation Sedation Scale (RASS)
Compare Richmond Agitation Sedation Scale (RASS) score at a different time point during the follow-up time. RASS score will be measured on a scale (from -5 = Unarousable to +4 = Combative where 0 = Alert and calm)
Patient Discomfort
Patient Discomfort due to device (Yes / no)
Bleeding
Bleeding at the site of device placement (Yes / No)
Interference with Daily Activities
Interference with activities of daily living due to the device (Yes/No)

Full Information

First Posted
February 2, 2023
Last Updated
October 9, 2023
Sponsor
DyAnsys, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT05742711
Brief Title
Efficacy of PENS of the Auricle as an Opioid Sparing Postoperative Analgesic Technique in Cancer Endometrium and Cancer Cervix Patients
Official Title
Efficacy of Percutaneous Electrical Neurostimulation (PENS)of the Auricle as an Opioid Sparing Postoperative Analgesic Technique in Cancer Endometrium and Cancer Cervix
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 16, 2023 (Actual)
Primary Completion Date
November 2023 (Anticipated)
Study Completion Date
November 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
DyAnsys, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Pain relief following laparotomy surgery requires a variety of techniques including invasive ones like epidural or nerve blocks along with different classes of drugs, out of which opioids are most predominant. Each of these drugs have with their own set of advantages and also side effects. An ideal common system of analgesia is not possible due to patient variability. And no drug is devoid of side effects. Hence the aim is to ensure effective analgesia using drugs or techniques which are minimally invasive with negligible side effects.
Detailed Description
Efficient post operative pain relief is an essential part of comprehensive recovery of patients. Conventional method of pain management of laparotomy surgeries in CA endometrium and cervix patients involves invasive techniques like epidural or selective nerve block coupled with a varied choice of analgesics like opioids, NSAID or acetaminophen, wherein each drug is associated with its own set of contraindications and side effects. Despite advances in analgesic regimen including multimodal analgesic regimen, opioids have been observed to remain the mainstay postoperative analgesia in cancer patients despite its well-established side effects. This double-blinded prospective interventional study is conducted to explore the alternative of percutaneous electrical nerve stimulation (PENS) devices for effective pain relief with minimal to no side-effects. The device will have tiny needles and a battery system that will be placed on and behind the patient's ear when they are under anesthesia. It acts by stimulating nerves around ear region by series of pain free impulse generation leading to centrally (brain) mediated response by altering certain chemical substances responsible for causing pain thereby providing relief for the patient.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cancer of Endometrium, Cancer of Cervix

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
48 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Treatment Group
Arm Type
Experimental
Arm Description
The group who have received PENS treatment using PrimaryRelief in addition to Injection paracetamol in a dosage of 15mg/kg every 6th hourly. Break through pain with NRS>4 will be managed with injection tramadol at 1mg/kg followed by 0.5mg/kg after 10mins in cases of persisting pain.
Arm Title
Control Group
Arm Type
Sham Comparator
Arm Description
The group who have received a sham device along with Injection paracetamol in a dosage of 15mg/kg every 6th hourly. Break through pain with NRS>4 will be managed with injection tramadol at 1mg/kg followed by 0.5mg/kg after 10mins in cases of persisting pain.
Intervention Type
Device
Intervention Name(s)
Primary Relief
Other Intervention Name(s)
Percutaneous Electrical Nerve Stimulator (PENS)
Intervention Description
Continuous neurostimulation with a set of pre-assigned stimulation parameters.
Intervention Type
Device
Intervention Name(s)
Primary Relief - Sham Device
Other Intervention Name(s)
Standard Treatment for Postoperative Pain
Intervention Description
Standard treatment with the application of sham device shall be followed with additional analgesics available if necessary.
Primary Outcome Measure Information:
Title
Numeric Rating Scale (NRS)
Description
The primary goal is to evaluate the efficacy of PENS treatment in the change in postoperative pain after cancer surgery compared to the control group. The pain is measured using the numerical rating scale (NRS). Pain Score will be measured on a scale (0 = no pain;10 = worst imaginable pain; lower scores indicate better outcome)
Time Frame
0 - 4 days; 0 hours, 2 hours, 4 hours, 8 hours, 12 hours, 18 hours, 24 hours, 36 hours, 48 hours, 72 hours, 96 hours. Outcomes will be reported as an average over each individual postoperative day and as an average over 5 days independently for rest.
Secondary Outcome Measure Information:
Title
Overall Postoperative analgesia and opioid requirement
Description
To evaluate the effect of treatment in reducing the overall postoperative analgesia and opioid requirement. We will record the total dose and duration of additional analgesics required from the immediate postoperative period till pod 4 in iv morphine equivalents.
Time Frame
0 - 4 days, duration and dose of all prescriptions are recorded.
Title
Patient Ambulation
Description
Evaluate the ease of patient ambulation by assessing associated Numeric Rating Scale (NRS) score (0 = no pain;10 = worst imaginable pain; lower scores indicate better outcome)
Time Frame
1 - 4 days; 24 hours, 36 hours, 48 hours, 72 hours, 96 hours.
Title
Record of Participant Bowel Movement Patterns
Description
Onset of Bowel Movements - POD 1/POD 2/ POD 3/ > POD3
Time Frame
0 - 4 days; Whenever the patient experiences the bowel movement.
Title
Richmond Agitation Sedation Scale (RASS)
Description
Compare Richmond Agitation Sedation Scale (RASS) score at a different time point during the follow-up time. RASS score will be measured on a scale (from -5 = Unarousable to +4 = Combative where 0 = Alert and calm)
Time Frame
0 - 4 days; 0 hours, 2 hours, 4 hours, 8 hours, 12 hours, 18 hours, 24 hours, 36 hours, 48 hours, 72 hours, 96 hours.
Title
Patient Discomfort
Description
Patient Discomfort due to device (Yes / no)
Time Frame
Time Frame: 0 - 4 days; Whenever the patient experiences the discomfort.
Title
Bleeding
Description
Bleeding at the site of device placement (Yes / No)
Time Frame
Time Frame: 0 - 4 days; Whenever the patient experiences bleeding.
Title
Interference with Daily Activities
Description
Interference with activities of daily living due to the device (Yes/No)
Time Frame
Time Frame: 0 - 4 days; Whenever the patient experiences disruption in daily activities.

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age >18 yrs Diagnosed with CA-endometrium OR CA -cervix of stage I/II and post RT CA cervix patients coming for hysterectomy Elective surgery Informed consent obtained ASA (American Society of Anaesthesiology) physical status 1-3 Exclusion Criteria: Patient refusal Cancer cervix other than the stages mentioned in inclusion criteria ASA PS >3 Emergency surgery, Laparoscopic and robotic procedures Unplanned postoperative ventilation Allergy/sensitivity to adhesive Active skin infection/lesion in the ear region H/O of seizure or cerebral disease H/O chronic pain and prolonged analgesic usage H/O opioid dependence H/O anxiety or psychiatric illness requiring treatment Pre-existing implantable/ electronic on demand device Patients who might require MRI in the study period Patients with transmissible diseases Patients with coagulopathies Absolute or relative contraindication to drugs used in the study
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Dr. Sahithya Sriman
Phone
+91-9840226923
Email
sahithyaadhithyan@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Robin Maria selvam, GNM.post B.Sc. nursing
Phone
+91-7259177671
Email
robinrose333@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dr. Sahithya Sriman, MBBS, MD
Organizational Affiliation
Cancer Institue, WIA,
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cancer Institute,(Wia)
City
Chennai
State/Province
Tamil Nadu
ZIP/Postal Code
600020
Country
India
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr. Sahithya Sriman,, MBBS, MD
Phone
+91-9840226923
Email
sahithyaadhithyan@gmail.com

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
26267984
Citation
Arponrat P, Pongrojpaw D, Tanprasertkul C, Suwannarurk K, Bhamarapravatana K. Postoperative Pain Relief in Major Gynaecological Surgery by Perioperative Parecoxib Administration: Thammasat University Hospital Study. J Med Assoc Thai. 2015 Jul;98(7):636-42.
Results Reference
result
PubMed Identifier
26600464
Citation
Pogatzki-Zahn E, Kutschar P, Nestler N, Osterbrink J. A Prospective Multicentre Study to Improve Postoperative Pain: Identification of Potentialities and Problems. PLoS One. 2015 Nov 24;10(11):e0143508. doi: 10.1371/journal.pone.0143508. eCollection 2015.
Results Reference
result
Links:
URL
https://www.ijsurgery.com/index.php/isj/article/view/2388
Description
Pattern of use of analgesics in post-operative pain management in adults undergoing laparotomy surgery: a prospective observational study

Learn more about this trial

Efficacy of PENS of the Auricle as an Opioid Sparing Postoperative Analgesic Technique in Cancer Endometrium and Cancer Cervix Patients

We'll reach out to this number within 24 hrs